443 related articles for article (PubMed ID: 35891550)
1. Omicron BA.1 Mutations in SARS-CoV-2 Spike Lead to Reduced T-Cell Response in Vaccinated and Convalescent Individuals.
Emmelot ME; Vos M; Boer MC; Rots NY; de Wit J; van Els CACM; Kaaijk P
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891550
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals.
Emmelot ME; Vos M; Boer MC; Rots NY; van Els CACM; Kaaijk P
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680141
[TBL] [Abstract][Full Text] [Related]
3. Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8
Redd AD; Nardin A; Kared H; Bloch EM; Abel B; Pekosz A; Laeyendecker O; Fehlings M; Quinn TC; Tobian AAR
mBio; 2022 Apr; 13(2):e0361721. PubMed ID: 35229637
[TBL] [Abstract][Full Text] [Related]
4. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
[TBL] [Abstract][Full Text] [Related]
5. T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine.
Li Y; Wang X; Jin J; Ma Z; Liu Y; Zhang X; Su B
J Med Virol; 2022 Aug; 94(8):3998-4004. PubMed ID: 35474581
[TBL] [Abstract][Full Text] [Related]
6. Landscape of T cell epitopes displays hot mutations of SARS-CoV-2 variant spikes evading cellular immunity.
Gan M; Cao J; Zhang Y; Fu H; Lin X; Ouyang Q; Xu X; Yuan Y; Fan X
J Med Virol; 2024 Feb; 96(2):e29452. PubMed ID: 38314852
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.
Kurhade C; Zou J; Xia H; Liu M; Yang Q; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Ren P; Xie X; Swanson KA; Shi PY
Emerg Microbes Infect; 2022 Dec; 11(1):1828-1832. PubMed ID: 35792746
[TBL] [Abstract][Full Text] [Related]
8. Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1.
Sohail MS; Ahmed SF; Quadeer AA; McKay MR
Viruses; 2024 Mar; 16(3):. PubMed ID: 38543838
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
Jeong HW; Kim SM; Jung MK; Noh JY; Yoo JS; Kim EH; Kim YI; Yu K; Jang SG; Gil J; Casel MA; Rare R; Choi JH; Kim HS; Kim JH; Um J; Kim C; Kim Y; Chin BS; Jung S; Choi JY; Song KH; Kim YD; Park JS; Song JY; Shin EC; Choi YK
Cell Rep Med; 2022 Oct; 3(10):100764. PubMed ID: 36182684
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
[TBL] [Abstract][Full Text] [Related]
11. Ablation of CD8
Swaminathan S; Lineburg KE; Panikkar A; Raju J; Murdolo LD; Szeto C; Crooks P; Le Texier L; Rehan S; Dewar-Oldis MJ; Barnard PJ; Ambalathingal GR; Neller MA; Short KR; Gras S; Khanna R; Smith C
Nat Commun; 2022 Oct; 13(1):6387. PubMed ID: 36302758
[TBL] [Abstract][Full Text] [Related]
12. Pre-existing SARS-2-specific T cells are predicted to cross-recognize BA.2.86.
Sette A; Sidney J; Grifoni A
Cell Host Microbe; 2024 Jan; 32(1):19-24.e2. PubMed ID: 38070502
[TBL] [Abstract][Full Text] [Related]
13. Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations.
Trombetta CM; Piccini G; Pierleoni G; Leonardi M; Dapporto F; Marchi S; Andreano E; Paciello I; Benincasa L; Lovreglio P; Buonvino N; Decaro N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Rappuoli R; Molesti E; Manenti A; Montomoli E
Commun Biol; 2022 Sep; 5(1):903. PubMed ID: 36056181
[TBL] [Abstract][Full Text] [Related]
14. Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity.
Muñoz-Alía MÁ; Nace RA; Balakrishnan B; Zhang L; Packiriswamy N; Singh G; Warang P; Mena I; Narjari R; Vandergaast R; Peng K-W; García-Sastre A; Schotsaert M; Russell SJ
mBio; 2024 Feb; 15(2):e0292823. PubMed ID: 38193729
[TBL] [Abstract][Full Text] [Related]
15. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
Muik A; Lui BG; Quandt J; Diao H; Fu Y; Bacher M; Gordon J; Toker A; Grosser J; Ozhelvaci O; Grikscheit K; Hoehl S; Kohmer N; Lustig Y; Regev-Yochay G; Ciesek S; Beguir K; Poran A; Vogler I; Türeci Ö; Sahin U
Cell Rep; 2023 Aug; 42(8):112888. PubMed ID: 37527039
[TBL] [Abstract][Full Text] [Related]
16. Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees.
Andreano E; Paciello I; Marchese S; Donnici L; Pierleoni G; Piccini G; Manganaro N; Pantano E; Abbiento V; Pileri P; Benincasa L; Giglioli G; Leonardi M; Maes P; De Santi C; Sala C; Montomoli E; De Francesco R; Rappuoli R
Nat Commun; 2022 Jun; 13(1):3375. PubMed ID: 35697673
[TBL] [Abstract][Full Text] [Related]
17. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.
Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K
Front Immunol; 2022; 13():946318. PubMed ID: 35928813
[TBL] [Abstract][Full Text] [Related]
18. Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2.
Pastorio C; Zech F; Noettger S; Jung C; Jacob T; Sanderson T; Sparrer KMJ; Kirchhoff F
Cell Host Microbe; 2022 Sep; 30(9):1255-1268.e5. PubMed ID: 35931073
[TBL] [Abstract][Full Text] [Related]
19. Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes.
Quandt J; Muik A; Salisch N; Lui BG; Lutz S; Krüger K; Wallisch AK; Adams-Quack P; Bacher M; Finlayson A; Ozhelvaci O; Vogler I; Grikscheit K; Hoehl S; Goetsch U; Ciesek S; Türeci Ö; Sahin U
Sci Immunol; 2022 Sep; 7(75):eabq2427. PubMed ID: 35653438
[TBL] [Abstract][Full Text] [Related]
20. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.
Gao Y; Cai C; Grifoni A; Müller TR; Niessl J; Olofsson A; Humbert M; Hansson L; Österborg A; Bergman P; Chen P; Olsson A; Sandberg JK; Weiskopf D; Price DA; Ljunggren HG; Karlsson AC; Sette A; Aleman S; Buggert M
Nat Med; 2022 Mar; 28(3):472-476. PubMed ID: 35042228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
